CRINETICS PHARMACEUTICALS IN (CRNX) Stock Income Statement
NASDAQ:CRNX - Nasdaq - US22663K1079 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 760.00K | 1.04M | 4.01M | 4.74M | 1.08M | |||
| Operating Expenses | 377.49M | 339.89M | 226.62M | 172.62M | 108.78M | |||
| Research and Development | 263.06M | 240.16M | 168.53M | 130.23M | 84.26M | |||
| Selling, General, and Administrative Expenses | 114.44M | 99.74M | 58.09M | 42.39M | 24.53M | |||
| Operating Income | -376.73M | -338.85M | -222.61M | -167.88M | -107.70M | |||
| Interest Income/Expense | 49.02M | 41.44M | 36.44M | 32.92M | 50.00K | |||
| Other Income/Expense | -537.00K | -519.00K | -23.16M | -27.94M | 10.00K | |||
| Income Before Taxes | -328.25M | -297.94M | -209.33M | -162.91M | -107.64M | |||
| Income Tax | N/A | 0.00 | N/A | N/A | N/A | |||
| Net Income | -328.25M | -298.41M | -214.53M | -163.92M | -107.64M | |||
| EBITDA | -373.49M | -336.07M | -221.51M | -166.90M | -106.78M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.82 | -3.69 | -3.69 | -3.15 | -2.80 | |||
| Non GAAP EPS | -3.82 | -3.71 | -3.70 | -3.14 | -2.80 | |||
| Statistics | ||||||||
| Profit Margin | -43191.05% | -28720.69% | -5345.85% | -3458.23% | -9966.67% | |||
| Operating Profit Margin | -49569.74% | -32613.47% | -5547.17% | -3541.77% | -9972.22% | |||
All data in USD